The Life Sciences team advised AbSci on its $125 million crossover financing.
AbSci is a leading synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics.
Proceeds will support AbSci's continued growth, including research and development activities and other strategic investments. Key areas of focus are integration and training of the Denovium Engine™ deep learning artificial intelligence platform AbSci acquired in January 2021, and ongoing expansion of core discovery capabilities including non-standard amino acid technologies.
The Goodwin team was led by Maggie Wong and Kingsley Taft and included Mulon Luo.
For more details, read the press release and articles in Portland Business Journal and GeekWire.